Buy & Sell Unilever plc (UL) – Unilever plc Price Today
Aura AI Summary
Key Stats
- $121.07BMarket Cap
- Consumer StaplesSector
- -17.07%3M Drawdown
- $146.81BEnterprise Value
- 4.06%Dividend Yield
- 3% Buy | 97% SellTrading Activity
- 105 daysTypical Hold Time
Unilever plc (UL) is currently valued at a market capitalization of $121.07B, with an enterprise value of $146.81B. Over the past 52 weeks, Unilever plc has traded between a low of $55.05 and a high of $74.59, highlighting its annual price range. Over the past three months, Unilever plc has recorded a drawdown of -17.07%, reflecting recent price volatility. Unilever plc offers a dividend yield of 4.06%, with the most recent dividend of $0.54 paid on 15 May 26. On average, investors hold Unilever plc for approximately 105 days, indicating typical investor behavior on the platform.
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Most Recent News
Investigation into Wealthfront's securities fraud continues amid sharp stock drops and deposit declines.
Glancy Prongay & Murray LLP is investigating Wealthfront Corporation for potential securities law violations after the company reported significant financial setbacks. Wealthfront's stock fell sharply following disclosures of large net deposit outflo...

ControlUp named Leader for third year in Gartner's 2026 Digital Employee Experience Magic Quadrant.
ControlUp has been recognized as a Leader for the third consecutive year in Gartner's 2026 Magic Quadrant for Digital Employee Experience (DEX) Management Tools. This highlights ControlUp's innovation in Autonomous Endpoint Management using agentic A...

Gilead and Merck halt lung cancer trial but report positive HIV drug Phase 3 results.
Gilead Sciences and Merck have stopped their Phase 3 trial combining Trodelvy and Keytruda for metastatic non-small cell lung cancer after it failed to show statistically significant benefits. However, they announced positive Phase 3 results for a ne...
